INT191265

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 8
Disease Relevance 2.50
Pain Relevance 1.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (PES1) nucleoplasm (PES1) nucleolus (PES1)
nucleus (PES1) intracellular (PES1)
Anatomy Link Frequency
fat 1
PES1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 140 97.64 Very High Very High Very High
Chronic pancreatitis 385 96.80 Very High Very High Very High
fibrosis 63 92.88 High High
Bile 63 84.76 Quite High
alcohol 28 62.44 Quite High
Potency 7 54.16 Quite High
Analgesic 7 50.52 Quite High
antagonist 14 27.76 Quite Low
abdominal pain 14 14.76 Low Low
Cholecystokinin 49 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Steatorrhea 119 98.36 Very High Very High Very High
Pain 133 97.64 Very High Very High Very High
Pancreatitis 385 96.80 Very High Very High Very High
Cystic Fibrosis 63 92.88 High High
Myocardial Infarction 2 80.64 Quite High
Weight Loss 7 78.76 Quite High
Food Poisoning 7 73.44 Quite High
Giardiasis 7 71.04 Quite High
Gastrointestinal Disease 7 65.36 Quite High
Aspergillus Infection 7 59.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In vitro and in vivo studies have been performed to evaluate the bioequivalence of PES using these recommendations. 91–93 All PES products evaluated in these tests were within the USP requirements for levels of amylase, lipase and protease and most preparations had far greater enzyme activity than the lower limit required by the USP.
Gene_expression (products) of PES
1) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0 Pain Relevance 0.03
Medium chain triglycerides are not recommended as they do not offer any additional improvement in lipid digestion in patients receiving PES.103
Gene_expression (receiving) of PES
2) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0.36 Pain Relevance 0.23
All of the PES preparations commercially available in 1992 contained adequate quantities of colipase for effective lipid digestion.70

Role of simultaneous acid supression

Gene_expression (preparations) of PES
3) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0.30 Pain Relevance 0.18
Isolated colipase deficiency has been demonstrated as a sole cause of steatorrhea in patients with PEI69 and is a potential cause of treatment failure in patients receiving PES.
Gene_expression (receiving) of PES associated with steatorrhea
4) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0.30 Pain Relevance 0.17
Based on these recommendations, the PES preparation must be able to produce 60 IU/min of lipase activity in postprandial chyme throughout the digestive period.
Gene_expression (preparation) of PES
5) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0.26 Pain Relevance 0.13
When to administer PES
Gene_expression (administer) of PES
6) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0.82 Pain Relevance 0.49
A novel PES product, TheraCLEC-Total (TCT) containing a proprietary formulation of bacterial lipase and fungal protease and amylase, is being developed to aid the digestion of macronutrients.58,59 CF patients with PEI who were treated with TCT experienced improvements in fat and nitrogen absorption, with the greatest improvement in patients with baseline fat absorption of less than 40%.
Gene_expression (product) of PES in fat associated with fibrosis
7) Confidence 0.27 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0.38 Pain Relevance 0.13
Thus, transmural LV pressure would clinically be measured as LV intracavitary pressure minus Pes, assuming that Pes represents cardiac surface pressure.
Gene_expression (pressure) of Pes
8) Confidence 0.06 Published 2005 Journal Crit Care Section Body Doc Link PMC1414045 Disease Relevance 0.08 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox